Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hansoh Pharmaceutical has announced that its fifth New Drug Application for Ameile, a third-generation EGFR-TKI drug, has been accepted by China’s National Medical Products Administration. This innovative treatment is aimed at adult patients with specific types of non-small cell lung cancer. Ameile represents a significant development in the pharmaceutical market, boosting Hansoh’s profile in cancer treatment innovations.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.